TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07502508: Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy

Sponsor: Biomea Fusion Inc. · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 60 pts

Competing Trials Overlap

13 Active Trials

Excess Burn Exposure

$2,357,200

Rescue Site Savings

+$1,560,400

Unlock Full NCT07502508 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07502508 Rescue Dossier →